AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3

Sitara-M 50/500 Tablet ER

Prescription Icon
Prescription Required

Marketer

Intas Pharmaceuticals Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Sitara-M 50/500 Tablet ER

Diabex Duo 50/500 Extended-Release tablets combine two medications to effectively manage elevated blood glucose in individuals with type 2 diabetes. This dual action helps mitigate serious diabetic complications like vision impairment and kidney disease, potentially lowering the risk of stroke or heart attack. Diabex Duo 50/500 ER may be used independently or in conjunction with other anti-diabetic therapies. Optimal results are achieved when combined with a balanced diet and regular physical activity. Dosage is personalized based on individual health status, blood glucose readings, and concurrent medications. Consuming the medication with food minimizes gastrointestinal discomfort. Consistent daily dosing, at the same time each day, maximizes therapeutic benefit; discontinuation should only occur under medical supervision. Adherence to the prescribed diet and exercise plan is crucial for successful diabetes management, as lifestyle significantly impacts blood sugar control. Common side effects include nausea, diarrhea, vomiting, stomach upset, headache, and pharyngitis. Hypoglycemia is a potential adverse event, especially when used with insulin or sulfonylureas; proper recognition and management of low blood sugar are essential. This medication isn't universally appropriate. Prior to commencing treatment, inform your physician of any existing kidney, liver, or heart conditions, pancreatic issues, or significant alcohol consumption. Pregnant or lactating individuals should consult their physician before use. Potential drug interactions exist; therefore, disclose all medications to your doctor to ensure treatment safety. Alcohol intake should be minimized due to its hypoglycemic effect. Kidney function and blood glucose levels will be monitored regularly throughout treatment.

Uses of Sitara-M 50/500 Tablet ER

Managing type 2 diabetes

Major Benefits of Sitara-M 50/500 Tablet ER:

Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the entire tablet; avoid chewing, crushing, or fracturing it. The Sitara-M 50/500 Tablet ER should be administered with a meal.

Common Side effects of Sitara-M 50/500 Tablet ER:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Sitara-M 50/500 Tablet ER:

Consume this medication precisely as your physician directs, adhering to the prescribed dosage and timeframe. Ingest the Sitara-M 50/500 Tablet ER whole; avoid chewing, crushing, or fracturing it. Administer this extended-release tablet with a meal.

How Sitara-M 50/500 Tablet ER works:

Sitara-M 50/500 Extended-Release tablets combine sitagliptin and metformin to manage blood sugar. Sitagliptin boosts insulin production by the pancreas, enhances insulin utilization, and decreases hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and improves insulin sensitivity. This dual action optimizes glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concurrent use of alcohol and Sitara-M 50/500 Tablet ER is inadvisable due to safety concerns.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Sitara-M 50/500 Extended-Release tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the potential advantages against any possible dangers prior to prescribing this medication. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Sitara-M 50/500 tablets are likely not safe for breastfeeding mothers. Preliminary human studies indicate potential transfer to breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Impaired driving is possible with both hypoglycemia and hyperglycemia. Refrain from driving if you experience these blood sugar irregularities.

KidneyKidneyCAUTION

Exercise caution when prescribing Sitara-M 50/500 Tablet ER to individuals with impaired renal function; dosage modification may be necessary. Consult a physician for guidance. Sitara-M 50/500 Tablet ER is contraindicated in patients exhibiting severe kidney disease. Close monitoring of kidney function is recommended during treatment.

LiverLiverUNSAFE

The extended-release Sitara-M 50/500mg tablet is likely inadvisable for individuals with hepatic impairment and its use should be avoided. Medical advice is recommended.

What if you forget to take Sitara-M 50/500 Tablet ER :

Should you forget a dose of Sitara-M 50/500 Extended-Release Tablet, take it immediately upon remembering. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual medication regimen. Avoid taking a double dose.

Facts to Know About Sitara-M 50/500 Tablet ER

LabelValue
Developing Habits No.
Type of Therapy Diabetes Management

FAQs on Sitara-M 50/500 Tablet ER

Sitara-M 50/500 Tablet ER combines sitagliptin and metformin to treat type 2 diabetes in adults. This medication improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
Prolonged Sitara-M 50/500 Tablet ER use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Sitara-M 50/500 Tablet ER may cause common side effects such as low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may also result in vitamin B12 deficiency.
Patients with known allergies to Sitara-M 50/500 Tablet ER components or excipients, or with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Sitara-M 50/500 Tablet ER with alcohol is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container, following the storage instructions on the label or packaging. Discard any unused medication; keep it out of reach of children, pets, and others.
Sitara-M 50/500 Tablet ER can cause lactic acidosis, a serious medical emergency resulting from excessive blood lactic acid (also known as MALA, or Metformin-associated lactic acidosis). This rare side effect necessitates avoiding the medication in patients with kidney disease, the elderly, or those who consume large amounts of alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If these occur, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Sitara-M 50/500 Tablet ER combines sitagliptin and metformin to manage type 2 diabetes in adults. This medication improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
Sitara-M 50/500 Tablet ER may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may also result in vitamin B12 deficiency.
Sitara-M 50/500 Tablet ER is contraindicated in patients with allergies to its components or excipients, and those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitara-M 50/500 Tablet ER with alcohol is unsafe and may heighten the risk of lactic acidosis.
Sitara-M 50/500 Tablet ER can cause lactic acidosis, a serious medical emergency resulting from excessive blood lactic acid (also known as Metformin-associated lactic acidosis or MALA). This rare side effect is more likely in patients with kidney disease, older adults, or those who consume significant amounts of alcohol, thus making it contraindicated in these groups. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these symptoms, discontinue Sitagliptin + Metformin immediately and seek medical attention.
Prolonged use of Sitara-M 50/500 Tablet ER can lead to vitamin B12 deficiency by impairing its absorption. This deficiency, if left untreated, may cause anemia, neurological issues such as tingling, numbness in extremities, weakness, urinary problems, cognitive changes, and ataxia. To mitigate this risk, supplemental vitamin B12 is recommended at least annually, according to some researchers.
Store this medication in its original, tightly closed container, following the instructions on the label or packaging. Discard any unused medication and keep it out of reach of children, pets, and others.
Sitara-M 50/500 Tablet ER combines sitagliptin and metformin to manage type 2 diabetes in adults. This medication improves blood sugar control when used with a healthy diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
Sitara-M 50/500 Tablet ER may cause common side effects such as low blood sugar (hypoglycemia), taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may also result in vitamin B12 deficiency.
Sitara-M 50/500 Tablet ER is contraindicated in patients with known allergies to its components or excipients, and those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitara-M 50/500 Tablet ER with alcohol is unsafe and may heighten the risk of lactic acidosis.
Sitara-M 50/500 Tablet ER can cause lactic acidosis, a serious medical emergency characterized by high blood lactic acid levels (also known as Metformin-associated lactic acidosis or MALA). This rare side effect is more likely in patients with kidney disease, older adults, or those who consume excessive alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged use of Sitara-M 50/500 Tablet ER can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container as directed on the label or packaging. Discard any unused medication and keep it out of reach of children, pets, and others.
Sitara-M 50/500 Tablet ER
94
MRP 109
13% off